Asbestos Cancer Information

Actos and Bladder Cancer : Bladder cancer treatment can include surgery, chemotherapy, radiation therapy, and immunotherapy. Although some of these treatments are used alone, often a combination of several treatments (i.e., both chemotherapy and surgery) is used for the most success. Selection of the most appropriate treatment is based on clinical staging, including pathological and ra­diographic information, and individual preference in close consultation with your physician. When choosing a blad­der cancer treatment, it is important that you consider not only the potential for cancer cure but also the side effects and quality of life impact of various treatments.

More information on Actos and Bladder Cancer

SURGICAL TREATMENT

Surgery plays an important role in both the staging and subsequent treatment of bladder cancer. Transurethral resection of a bladder tumor (TURBT) is the initial treat­ment step in the vast majority of patients with bladder cancer. TURBT provides valuable staging information, and pathological results from these procedures are used to make further decisions regarding what, if any, addi­tional therapy is needed. The gold standard treatment for muscle-invasive bladder cancer is radical cystectomy (removal of the bladder). Advances in surgical technique and anesthesia have reduced the complications associated with this procedure in the last two decades. The develop­ment of continent urinary diversion, which allows one to empty the bladder through the urethra, is an option for certain patients. Minimally invasive procedures such as laparoscopic or robotic-assisted radical cystectomy may also be treatment options. In addition, bladder-sparing procedures (either with partial removal of the bladder or aggressive TURBT frequently in combination with che­motherapy and/or radiation therapy) have allowed some patients to treat their cancer while leaving their blad­ders intact. Advances in surgical techniques continue to this day with the development of minimally invasive approaches to cystectomy. Both robotic-assisted and lapa­roscopic radical cystectomy have been performed safely in highly specialized centers and have the potential for decreased morbidity and a shorter period of recovery, but longer term follow-up is needed to determine if these pro­cedures are equivalent to open surgical techniques.

Information from other sources on Actos and Bladder Cancer

TURBT is often the first procedure you will have once diagnosed with a bladder tumor. This surgery is typically performed under general or spinal anesthesia as an out­patient procedure and without any incision, endoscopically through the urethra, which means a cystoscope is placed through the urethra and into the bladder. Through this scope your urologist can see the inside of your bladder and has the ability to resect, or remove, tumors in the bladder under direct vision using electrocautery. The electrocautery is also used to control bleeding after the resection is com­pleted. TURBT is extremely important for the staging of bladder tumors but can also be therapeutic for lower stage bladder cancers. Once the tumor has been removed, it can be analyzed under the microscope by a pathologist. The pathological findings dictate further treatment decisions. If the tumor is low grade and noninvasive, you will likely not need any further therapy at this point except for close follow-up.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

Actos and Bladder Cancer

Actos and Bladder Cancer : An intravenous pyelogram (IVP) is an X-ray study that shows the general outline of the kidneys and better detail of the collecting system than an ultra­sound. X-ray contrast is given to the patient intra­venously. The kidneys then filter and concentrate the contrast, creating an image on an X-ray taken a few minutes after the injection is given. A small tumor or stone inside the collecting system can be seen as a dark spot inside the collecting system. Historically, the IVP was a common test to evaluate upper tracts. However, due to the decreased cost of CT scans and the increased availability, it has largely been replaced by CT scanning.

CT scanners use X-rays to create a detailed image of the internal organs. The scanner takes many X-rays at once and uses a computer to combine all of the images into the one picture that you see. When getting a CT scan of the kidneys, the patient is usually scanned three times. The first scan is per­formed without contrast and will reveal any kidney stones. The second scan is performed with contrast, which helps to show tumors in the kidneys. The third scan is obtained a few minutes later, after the kidney has had time to process the contrast. The contrast fills the collecting system similar to the IVP but with greater detail. A CT scan is very good for seeing tumors in both the kidneys and the col­lecting system. In addition to the ability to see the kidneys and ureters better, the CT scan allows for visualization of the entire abdomen and lymph nodes, helping to identify metastases or unrelated diseases. Over the last several years, the cost of CT scans has come down, and the availability of scan­ners to patients has increased, making the CT scan the most common upper tract study. As with the IVP test, CT scans meant to examine the kidneys

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

Although ureteroscopy is not technically an “upper tract study,” it gives us the most definitive examina­tion. It is similar to cystoscopy but uses a smaller scope. In the operating room or well-equipped office, the ureteroscope is carefully passed into the ureter as it opens into the bladder. This allows the urologist to see the inside of the ureter. It is gently passed all of the way up the ureter into the kidney. Like cys­toscopy, there are both rigid and flexible uretero- scopes. The flexible scope allows doctors to see all or most of the deep corners of the collecting system within the kidney. Biopsies of any suspicious areas can be taken and sent to pathology for analysis. Although ureteroscopy provides the best view of the collecting system, it usually requires anesthesia, and there is some small risk of damage to the kidney or ureter; thus, it is usually reserved for those patients who have had an abnormal upper tract study.

Information from other sources on Actos and Bladder Cancer

Cysview (hexaminolevulinate hydrochloride, GE health­care) has recently been approved as an optical imaging agent for use in the cystoscopic detection of non-muscle invasive papillary bladder cancer among patients sus­pected or known to have lesion(s) on the basis of prior cystoscopy. When used in combination with blue light (fluorescence) cystoscopy (Karl Storz D-Light C Pho­todynamic Diagnostic [PPD] system) it identified at least 1 more noninvasive papillary bladder tumor than rou­tine cystoscopy in about one third of the patients with such tumors. It is also useful in detecting carcinoma in situ, identifying 28% more patients with carcinoma in situ than standard cystoscopy.

Urine cytology is commonly used to screen for bladder cancer in patients who have hematuria as well as to monitor for recurrences in patients who are being treated for bladder cancer. Overall, urine cytology is able to detect 40% to 60% of bladder cancers, but the ability of cytology to detect a tumor varies depending on the grade, stage, and location of the tumor. In low-grade, low- stage tumors, cytology will detect only 25% to 40% of the tumors. It will perform better as the grade and stage of the tumor increase, with the best detection rate being for carcinoma in situ. Cytology detects approximately 90% of cases of carcinoma in situ.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer : Bladder cancer is a common cancer of the urinary tract. It is the fourth leading cause of cancer-related death among men and the seventh among women. Clinical management of bladder cancer is challenging because of the heterogeneity among bladder tumors with respect to invasion and metastasis and frequent occurrence of new tumors in the bladder among patients treated with bladder preservation treat­ments. Due to these factors it has been said that the cost per patient of bladder cancer from diagnosis to death is the highest of all cancers. In addition to it being a significant health problem, bladder cancer is an interesting cancer to study in many ways than one. For example, environmental factors such as cigarette smoking and other carcinogens play a major role in the development of transitional carci­noma of the bladder, whereas schistosomiasis, a protozoan infection, results in squamous cell carcinoma of the bladder. Different molecular pathways with distinct molecular signatures appear to be involved in the development of low-grade versus high-grade bladder tumors. Currently being monitored by an invasive endoscopic procedure, cystectomy, with urine cytology as an adjunct, bladder cancer is at the forefront of developing cancer biomarkers for noninvasive detection. Due to the differences in the invasive and metastatic potential of bladder tumors, treatment options differ depending upon the grade and stage of the tumor. New advances are being made in treatment options to improve the outcome and quality of life for patients with bladder cancer. Similarly, new molecular nomograms are being dis­covered to predict treatment outcome so that individualized treatment options can be offered to patients.

More information on Actos and Bladder Cancer

This new text book on bladder cancer is organized to give both the clinicians and laboratory investigators state-of-the art information on basic science and clinical aspects of bladder cancer. Organizing this book that includes both the molecular basis as well as clinical practices in the management of bladder cancer would not have been possible without the invaluable contributions of the authors of each chap­ter. These authors who are experts in various aspects of bladder cancer were assembled from institutions in different parts of the world. All of these authors were generous with their time and commitment for bringing the readers up-to-date infor­mation on current advances in each area of bladder cancer. In addition, these experts have provided critical evaluation of the material presented in each chapter. Therefore, as editors of this book it has been our privilege to work with each contributor and we believe that this book will serve as a comprehensive reference on bladder cancer.

Information from other sources on Actos and Bladder Cancer

Although, the readers are encouraged to read the entire book, we would like to present the highlight of each chapter in order to guide the readers to select the mate­rial of interest. Chapters 1-9 focus on molecular basis of bladder cancer, translational research into the areas of tumor markers, and standard mode of bladder diagnosis and detection. Chapters 10-22 focus on clinical aspects of bladder cancer.Smoking is well known; however, in Chap. 1 on epidemiology of bladder cancer, Dr. Ribal reminds us that other causes like occupational exposure, genetic predis­position, and infection are also linked to the development of bladder cancer. Bladder cancer is a carcinogenesis-driven cancer, with polycyclic aromatic hydro­carbons (PAH) and aromatic amines having causal links. Chapter 2 by Escudero, Shirodkar, and Lokeshwar focuses on xenobiotic metabolisms that convert PAH and aromatic amines into active carcinogens and on genetic polymorphisms that increase the risk for bladder cancer development. The chapter discusses theories of bladder cancer development (field cancerization versus clonal origin) and chromo­somal aberrations associated with bladder cancer.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer : Ureteral injury may occur when a tumor covers the ureter in the bladder. The ureter may be obscured by a bladder tumor, and the urologist may inadvertently resect it along with the tumor. In general, cutting current to remove a bladder tumor does not usually lead to long lasting problems as compared to cauterization, which is more likely to cause permanent blockage or obstruction of the ureter. If the urologist is working in the area of the ureter, he should avoid cauterization as much as possible. He may ask the anesthetist to inject an intravenous coloring agent which will turn the urine blue

and allow visualization of the ureter. If he knows a ureter may be in jeopardy, he may insert a stent (a small plastic tube that traverses the ureter) for several weeks to allow the ureter to heal in an open fashion.

Urethral injury is infrequent and is almost always in males. A stricture or narrowed area of the urethra may result from irritation or injury from the resectoscope pressing on the urethra. Individuals that develop strictures complain of difficulty urinating, experiencing a slow or split stream. Strictures are usually readily handled with a number of urologic procedures.

More information on Actos and Bladder Cancer

Bladder tumor “seeding” may occur during the procedure. As the tumors are resected, cancer cells are released into the irrigant which fills the bladder. These cells may implant in other areas of the bladder traumatized during the procedure. It should be understood that the bladder is generally filled with urine, and tumor cells can naturally implant at other locations even without surgery. Implantation can be lessened during surgery by avoiding injury to other bladder areas and by the use of adjuvant intravesical chemotherapy. There have been numerous studies over the past decade showing a number of chemotherapy agents can be effective in decreasing initial tumor recurrence, possibly by preventing seeding. Reduction in recurrence may however be short lived. Previously, it was common practice to obtain multiple random bladder biopsies at the time of initial tumor resection. This was recommended to rule out the possibility of hidden CIS. Understanding these biopsy sites may increase the possibilities of tumor recurrence by tumor seeding, biopsies are now often limited to areas adjacent to the tumors removed and suspicious appearing areas only. CIS can be ruled out by using cytology, or by obtaining biopsies during future cystoscopy after the tumor has already been removed. When dealing with low grade tumors, random biopsies of the bladder will rarely show cancer.^[1]

Information from other sources on Actos and Bladder Cancer

After your procedure, depending on the level of anesthesia and the extent of surgery, you will be brought either to the recovery room or back to the area where you were first prepared for your procedure. You will be released to home only when you have fully recovered from you anesthetic and are doing well.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer : The recurrence rate for superficial bladder cancer can be as high as 60-90%. Recurrences can cause bleeding and other difficulties and are best handled sooner rather than later. In addition, depending on the initial tumor grade and stage, progression to a more serious form of bladder cancer is an ongoing concern. Surveillance cystoscopy is therefore recommended.

More information on Actos and Bladder Cancer

Cystoscopy is still the best means to check for recurrent disease. It is however, an invasive procedure and should be accomplished only as often as required. For solitary, low grade, non invasive disease, follow up cystoscopy can be accomplished with the flexible cystoscope if available. If negative at three months, further cystoscopic exams can be done yearly and eventually lengthened even further. For those with multiple tumors, large tumors, high grade tumors or those who also have CIS, frequent cystoscopies, initially every three months are called for. As long as there are no recurrences, the time between cystoscopies can be lengthened. Cytology can also be utilized to reduce the number of cystoscopies. If recurrence or progression does occur, heightened scrutiny is again called for.

Information from other sources on Actos and Bladder Cancer

BESIDES A BLADDER TUMOR, MY CT SCAN INDICATED MY KIDNEY IS SWOLLEN BECAUSE OF A BLOCKAGE OF MY URETER. DID THE BLADDER TUMOR CAUSE THIS BLOCKAGE AND DOES IT MEAN MY PROGNOSIS IS WORSE?

There are many medical conditions that may result in hydroureteronephrosis (swelling of the kidney and ureter), having nothing to do with bladder cancer. It is also true large bladder tumors may grow into the wall of the bladder and cause ureteral obstruction at the level of the bladder. When this is found, the prognosis is usually poor, as the tumors involved are usually high grade and deeply invasive. On occasion, a superficial low grade tumor may grow directly into the ureteral opening. In this situation, prognosis is not generally any worse, as the blockage has not occurred from an invasive tumor.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer : The urinary system (Figure i-i) is very important and has a pretty tough job to do in everyone’s body. It filters your blood and produces waste products in the form of urine. More importantly, it allows you to store urine until it is convenient to urinate. Just think, if we couldn’t store urine, then we would constantly leak waste products. This would make life very difficult and get in the way of things we do during the course of a normal day. The human urinary system is made up of the kidneys, ureters, bladder, and urethra. Men have a prostate gland in addition to the previously mentioned components.

More information on Actos and Bladder Cancer

Your kidneys are two bean-shaped organs that reside in the rear of your abdomen, just under the diaphragm on the left and below the liver on your right side. The kidneys filter blood and produce urine. They are extremely important to life and work extremely hard to filter waste from your bloodstream. Just imagine, the kidneys filter approximately 20 percent of your blood each minute. Although most people have two kidneys, some individuals have one and do just fine. The kidneys function independently, and when one is not working as well, the other compensates and filters more blood. In addition to filtering blood and producing urine, your kidneys help to regulate your blood pressure. They produce special hormones and control the salt and water balance in your body. Normally, the kidneys do not release blood cells into urine. This is why it’s important to be evaluated by a doctor if you have blood in your urine.

Information from other sources on Actos and Bladder Cancer

URETERS

After urine is formed by the kidneys, special nerves and muscles in the renal pelvis propel urine downward into the ureters. The ureters are small tubes, very much like the renal pelvis, that allow passage of urine from die kidneys down to the bladder. They function as drainage pipes for the kidney. The ureters have nerves and layers of muscle that propel urine to the bladder. There is so much that your body does that you may not realize. Like the renal pelvis, the ureters are also lined with transitional cells serving as a continuation of die uxothelium.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer :

BLADDER

The ureters connect to the bladder, which is a muscular, balloon-lilce structure in the pelvis. The bladder functions as the storage unit of the urinary system. It can hold upward of 500-600 mL (2 cups) of urine. Hie bladder is very thick and elastic with multiple layers .

An inner layer made up of transitional cells forming the urothelium; under this lies a thin layer (the lamina propria), with blood vessels supplying the bladder; and finally a thick muscular layer that contracts to empty your bladder. There is a layer of fat surrounding the muscular layer.

The bladder expands in relation to the amount of fluid inside of it Bladder contraction is under complex control by your central nervous system. When your bladder contracts during urination, urine passes though the urethra before leaving your body. The inner cells, closest to the bladder, are transitional cells, whereas the cells closest to the outside of the body are squamous cells resembling skin. Although the urethra has different lengths in men and women, it functions the same. In men, the urethra passes through the prostate gland near the bladder.

More information on Actos and Bladder Cancer

PROSTATE

The prostate, a walnut-sized organ that lies at the base of the bladder in men, plays a role in male fertility. Along with the seminal vesicles, the prostate gland produces fluid that helps sperm after ejaculation. Although the urethra passes through the prostate, the gland itself does not add much, if anything, to the volume of urine that reaches the bladder. As the urethra passes through the prostate, it is lined by transitional cells comprising the urothelium. Therefore, tilings that affect the urothelium can affect the prostate as well. This is very important when it comes to staging bladder cancer.

The urethra is a hollow tube lined with transitional cells at its beginning that connects the bladder to the outside world. The structure of the urethra is different in men and women. The urethra is short in women and is much longer in men due to the presence of the penis. The cells lining the

urethra change along its length. The inner cells, closest to the

Information from other sources on Actos and Bladder Cancer

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com